Trial reportThe American journal of cardiology2009
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Trial report in The American journal of cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01974297 (Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Pooled it
- Lipid-lowering efficacy of atorvastatin.The Cochrane database of systematic reviews · 2015 · on this mapPooled it
- Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.Cardiovascular drugs and therapy · 2012 · on this mapTrial
- Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.Diabetes care · 2012Trial
- Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.Cardiovascular drugs and therapy · 2011Trial
- The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.Diabetes care · 2010Trial
- Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.Clinical drug investigation · 2010Trial
- Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins.Frontiers in cardiovascular medicine · 2026Review
- Fixed Combination for the Treatment of Dyslipidaemia.Current atherosclerosis reports · 2023Review
- Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2016Review
- Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia.Journal of cardiovascular translational research · 2014Article
- A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.Cardiology research · 2013Review
- A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.Cardiovascular drugs and therapy · 2012 · on this mapReview
- Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.Vascular health and risk management · 2012Review
- Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.Mayo Clinic proceedings · 2011Review
- Pharmacological strategies for lowering LDL cholesterol: statins and beyond.Nature reviews. Cardiology · 2011Review
- Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Vascular health and risk management · 2010Review
- Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.Vascular health and risk management · 2010Review
- Therapeutic options to further lower C-reactive protein for patients on statin treatment.Current atherosclerosis reports · 2010Review
- A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy.Clinical pharmacology : advances and applications · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering drugs often fails to achieve all lipid targets. This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia. A total of 613 patients with LDL cholesterol > or =130 mg/dl, TG > or =150 mg/dl, and HDL cholesterol <40 mg/dl for men and <50 mg/dl for women were randomly assigned to ABT-335 (135 mg), atorvastatin (20, 40, or 80 mg), or combination therapy (ABT-335 + atorvastatin 20 or 40 mg) and treated for 12 weeks. Combination therapy with ABT-335 + atorvastatin 20 mg resulted in significantly greater improvements in TG (-45.6% vs -16.5%) and HDL cholesterol (14.0% vs 6.3%) compared with atorvastatin 20 mg and LDL cholesterol (-33.7% vs -3.4%) compared with ABT-335. Similarly, significantly greater improvements were observed with ABT-335 + atorvastatin 40 mg in TG (-42.1% vs -23.2%) and HDL cholesterol (12.6% vs 5.3%) compared with atorvastatin 40 mg and LDL cholesterol (-35.4% vs -3.4%) compared with ABT-335 monotherapy. Combination therapy also improved multiple secondary variables. Combination therapy was generally well tolerated with a safety profile consistent with those of ABT-335 and atorvastatin monotherapies. No rhabdomyolysis was reported. In conclusion, ABT-335 + atorvastatin combination therapy resulted in more effective control of multiple lipid parameters than either monotherapy and may be an appropriate therapy for patients with mixed dyslipidemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.